

# Step-by-Step Dosing and Administration Guide

RoActemra® (tocilizumab) intravenous (IV) and subcutaneous (SC) formulations for Rheumatoid Arthritis

**A guide to assist healthcare professionals with the dose, preparation and administration of RoActemra therapy in patients with Rheumatoid Arthritis**



This educational material is provided by Roche Products Ltd and is mandatory as a condition of the Marketing Authorisation in order to minimise important selected risks

Full prescribing information can be found in the RoActemra Summary of Product Characteristics (SmPC): [www.medicines.org.uk](http://www.medicines.org.uk)

## Contents

<b>Part I – Intravenous (IV) administration of RoActemra by infusion</b>	<b>3</b>
1. Weigh patient and calculate RoActemra dose	4
2. Gather all necessary supplies	5
3. Take baseline assessments	5
4. Prepare the patient for infusion	6
5. Prepare the RoActemra infusion	6
6. Begin the RoActemra infusion	7
Frequently asked questions: RoActemra IV	8
<b>Part II – Subcutaneous (SC) administration of RoActemra by injection using a pre-filled syringe</b>	<b>11</b>
1. Gather all necessary supplies	12
2. Take baseline assessments	12
3. Preparation for injection with the pre-filled syringe	13
4. Administering the injection with the pre-filled syringe	16
Frequently asked questions: RoActemra SC	18



## Part I – Intravenous (IV) administration of RoActemra by infusion

### This section will walk you through the RoActemra infusion process in 6 steps

#### Before therapy begins

Before beginning RoActemra therapy, it is important that you review the Package Leaflet with each patient. This dosing guide contains valuable information that will help your patients fully understand what they may expect from their treatment.

- RoActemra alert cards and other information can be requested from your sales representative or Medical Information. If you have questions or concerns, please email [medinfo.uk@roche.com](mailto:medinfo.uk@roche.com) or call +44 (0)1707 361010
- For full information, see the Summary of Product Characteristics (SmPC) and the Package Leaflet, which can be found on the Electronic Medicines Compendium (EMC) website: [www.medicines.org.uk/emc](http://www.medicines.org.uk/emc)



## 1. Weigh patient and calculate RoActemra dose

RoActemra dosing is calculated based on each patient's weight. Verify the patient's weight, then locate it on the chart to find the corresponding dose and recommended vial combination.

If the patient's dose has been calculated prior to the infusion date, take his or her weight to make sure that it has not changed from the time of the original calculation to require a change in dose. If the patient's weight has changed, contact the prescriber to discuss whether a dosing change is needed. Refer to the chart to check whether a dosing adjustment is necessary.

8 mg/kg				
Weight (kg)	Weight (lbs)	Dose (mg)	Dose (ml)	Vial combinations
50	110.0	400	20.0	400
52	114.4	416	20.8	400 + 80
54	118.8	432	21.6	400 + 80
56	123.2	448	22.4	400 + 80
58	127.6	464	23.2	400 + 80
60	132.0	480	24.0	400 + 80
62	136.4	496	24.8	400 + 80 + 80
64	140.8	512	25.6	400 + 80 + 80
66	145.2	528	26.4	400 + 80 + 80
68	149.6	544	27.2	400 + 80 + 80
70	154.0	560	28.0	400 + 80 + 80
72	158.4	576	28.8	400 + 80 + 80
74	162.8	592	29.6	400 + 80 + 80
76	167.2	608	30.4	400 + 80 + 80 + 80
78	171.6	624	31.2	400 + 80 + 80 + 80
80	176.0	640	32.0	400 + 80 + 80 + 80
82	180.4	656	32.8	400 + 80 + 80 + 80
84	184.8	672	33.6	400 + 80 + 80 + 80
86	189.2	688	34.4	400 + 80 + 80 + 80 + 80
88	193.6	704	35.2	400 + 80 + 80 + 80 + 80
90	198.0	720	36.0	400 + 80 + 80 + 80 + 80
92	202.4	736	36.8	400 + 80 + 80 + 80 + 80
94	206.8	752	37.6	400 + 80 + 80 + 80 + 80
96	211.2	768	38.4	400 + 80 + 80 + 80 + 80
98	215.6	784	39.2	400 + 80 + 80 + 80 + 80
≥100	>220.0	800	40.0	400 + 400

RoActemra dosing is calculated based on each patient's weight as follows:

**For the 8 mg/kg dose: Patient weight (kg) x 8 = RoActemra 8 mg/kg dose**

For individuals whose body weight is more than 100 kg, doses exceeding 800 mg per infusion are not recommended.

Once the dose is calculated, choose the vial combination of RoActemra that best matches the patient's needs. RoActemra is available in three different dosing vials:

400 mg (20 ml) vials   200 mg (10 ml) vials   80 mg (4 ml) vials

Inspect the vials for particulate matter and discolouration. Only solutions which are clear to opalescent, colourless to pale yellow and free of visible particles should be used.

## 2. Gather all necessary supplies

You will need:

- RoActemra at room temperature
- Syringes and large-bore needles
- One primary infusion set
- One 100 ml bag of 0.9% (9 mg/ml) sterile, non-pyrogenic sodium chloride solution for injection
- One intravenous (IV) catheter
- Gauze
- Tourniquet
- Gloves
- Alcohol/cleansing wipes

## 3. Take baseline assessments

Take baseline assessments to ensure the patient is healthy enough to receive the infusion. Vital signs should include:

- Blood pressure
- Temperature
- Pulse

**Also ask the patient if they:**

- Are taking other medicines. This includes prescription and non-prescription medications, vitamins and herbal supplements
- Are taking any other medications to treat Rheumatoid Arthritis (RA) such as: Methotrexate (MTX), Enbrel® (etanercept), Humira® (adalimumab), Remicade® (infliximab), MabThera® (rituximab), Orenzia® (abatacept), Kineret® (anakinra), Cimzia® (certolizumab pegol), or Simponi® (golimumab)
- Have had any allergic reactions to previous medications, including RoActemra
- Are pregnant, might be pregnant, intend to become pregnant, or are breast feeding
- Have an infection or are being treated for an infection; have had or now have hepatitis or any disease of the liver; have a history of stomach ulcers or diverticulitis; have had or now have impaired lung function (e.g. interstitial lung disease)
- Have diabetes or other underlying conditions that may predispose them to infections
- Are planning or are scheduled to have surgery; have had a recent vaccination (such as a flu shot) or are scheduled to have one
- Have cancer, cardiovascular risk factors, such as raised blood pressure and raised cholesterol levels, or moderate to severe kidney function problems

Enbrel® is a registered trademark of Amgen Inc. and Pfizer Inc.; Humira® is a registered trademark of AbbVie; Remicade® is a registered trademark of Schering Plough Corporation; MabThera® is a registered trademark of F. Hoffmann-La Roche Ltd; Orenzia® is a registered trademark of Bristol-Myers Squibb; Kineret® is a registered trademark of Amgen Inc.; Cimzia® is a registered trademark of the UCB Group of Companies; Simponi® is a registered trademark of Centocor Inc. and Schering-Plough Corporation.



## 4. Prepare the patient for the infusion

RoActemra does not require premedication.

Review the Package Leaflet with the patient and answer any questions he or she might have.



## 5. Prepare the RoActemra infusion

RoActemra should not be infused concomitantly in the same IV line with other medications.

No physical or biochemical compatibility studies have been conducted to evaluate the co-administration of RoActemra with other medications.

**RoActemra is a ready-mix solution and requires no reconstitution.** The expiry date should always be checked before use. The RoActemra concentrate for IV infusion should be diluted to 100 ml by a healthcare professional using aseptic technique.

- RoActemra should be refrigerated for storage and the fully diluted RoActemra solution should be allowed to reach room temperature before it is infused. After dilution, the prepared solution for infusion is physically and chemically stable in sodium chloride 9 mg/ml (0.9%) at 30°C for 24 hours. From a microbiological point of view, the prepared solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally be no longer than 24 hours at 2–8°C, unless dilution has taken place in controlled and validated aseptic conditions. RoActemra solutions do not contain preservatives; therefore, unused product remaining in the vials should not be used
- From a 100 ml infusion bag, withdraw a volume of sterile, non-pyrogenic sodium chloride 0.9% (9 mg/ml) solution for injection equal to the volume of the RoActemra solution required for the patient's dose
- Slowly add RoActemra concentrate for IV infusion from each vial into the infusion bag. To mix the solution, gently invert the bag to avoid foaming
- Parenteral medicinal products should be inspected visually for particulate matter and discoloration prior to administration. Only solutions which are clear to opalescent, colourless to pale yellow and free of visible particles should be diluted
- Dispose of the needle and syringe in a sharps container when finished

## 6. Begin the RoActemra infusion

**The infusion should be administered over one hour. It must be administered with an infusion set and should never be administered as an IV push or bolus.**

Prior to the infusion, inform the patient that serious allergic reactions including anaphylaxis have been reported in association with RoActemra. Such reactions may be more severe, and potentially fatal, in patients who have experienced allergic reactions during previous treatment with RoActemra even if they have received premedication with steroids and antihistamines. Most allergic reactions occur during infusion or within 24 hours of RoActemra administration, although allergic reactions can occur at any time. If an anaphylactic reaction or other serious hypersensitivity/serious infusion-related reaction occurs, administration of RoActemra should be stopped immediately, appropriate therapy initiated and RoActemra should be permanently discontinued. Fatal anaphylaxis has been reported after marketing authorisation during treatment with RoActemra IV.

Instruct the patient to **seek immediate medical attention** if they notice any of the following signs or symptoms of systemic allergic reactions:

- Rash, itching or hives
- Shortness of breath or trouble breathing
- Swelling of the lips, tongue or face
- Chest pain
- Feeling dizzy or faint
- Severe stomach pain or vomiting
- Hypotension

Once the infusion is completed, remove the catheter and dispose of all supplies properly, clean and bandage the infusion site and check the patient's vital signs.



## Frequently asked questions: RoActemra IV

### How do I store RoActemra vials?

RoActemra must be refrigerated at 2–8°C. Do not freeze. Protect the vials from light by storing in the original package until time of use.

### What vial sizes are available, and which should we stock?

RoActemra is available in three different dosing vials: 400 mg (20 ml), 200 mg (10 ml) and 80 mg (4 ml). As the dosing of RoActemra IV is calculated based upon patient weight, you may need a supply of all three dosing vials on hand in order to select the correct vial combination for each patient.

### Do I need to administer premedication?

No premedication is required before administering RoActemra. However, an IV of medication-free 0.9% (9 mg/ml) sterile, non-pyrogenic sodium chloride solution should be administered to open and prepare the patient's vein for the infusion.

### How do I prepare RoActemra for infusion? What diluents can I use?

RoActemra concentrate for IV infusion should be diluted to 100 ml using aseptic technique.

- From a 100 ml infusion bag, withdraw a volume of 0.9% (9 mg/ml) sterile, non-pyrogenic sodium chloride solution for injection equal to the volume of the RoActemra concentrate required for the patient's dose, under aseptic conditions
- Slowly add the required amount of RoActemra concentrate for IV infusion from each vial into the infusion bag. To mix the solution, gently invert the bag to avoid foaming
- RoActemra should be refrigerated for storage and the fully diluted RoActemra solution should be allowed to reach room temperature before it is infused
- Parenteral medicinal products should be inspected visually for particulate matter and discolouration prior to administration. Only solutions which are clear to opalescent, colourless to pale yellow and free of visible particles should be diluted. The expiry date should always be checked before use
- Dispose of the needle and syringe in sharps container when finished

### What is the infusion duration?

RoActemra is administered over one hour. It must be administered with an infusion set and should never be administered as an IV push or bolus.

### How do I store the diluted infusion? What is the stability of RoActemra?

After dilution, the prepared solution for infusion is physically and chemically stable in sodium chloride 9 mg/ml (0.9%) at 30°C for 24 hours. From a microbiological point of view, the prepared solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user and would normally be no longer than 24 hours at 2–8°C, unless dilution has taken place in controlled and validated aseptic conditions. RoActemra solutions do not contain preservatives; therefore, unused product remaining in the vials should not be used.

### What should I look for during the infusion?

Watch the patient closely for any signs and symptoms of hypersensitivity, including anaphylaxis. Most allergic reactions occur during infusion or within 24 hours of RoActemra administration, although allergic reactions can occur at any time. If an anaphylactic reaction or other serious hypersensitivity/serious infusion-related reaction occurs, administration of RoActemra should be stopped immediately, appropriate therapy initiated and RoActemra should be permanently discontinued.

Instruct the patient to **seek immediate medical attention** if they notice any of the following signs or symptoms of systemic allergic reactions after receiving RoActemra:

- Rash, itching or hives
- Shortness of breath or trouble breathing
- Swelling of the lips, tongue or face
- Chest pain
- Feeling dizzy or faint
- Severe stomach pain or vomiting
- Hypotension

### What kinds of side effects and reactions can occur during or after the infusion, and how common are they?

The most common side effects with RoActemra are upper respiratory tract infections, nasopharyngitis, headache, hypertension and increased alanine transaminase (ALT) levels.

Adverse events associated with infusion (selected events occurring during or within 24 hours of infusion) were reported by 6.9% of patients in the RoActemra 8 mg/kg plus DMARD group and 5.1% of patients in the placebo plus DMARD group. Events reported during the infusion were primarily episodes of hypertension; events reported within 24 hours of finishing an infusion were headache and skin reactions (rash, urticaria). These events were not treatment-limiting.

The rate of anaphylactic reactions, occurring in a total of 6 out of 3,778 patients (0.2%), was several-fold higher with the 4 mg/kg dose, compared to the 8 mg/kg dose. Clinically significant hypersensitivity reactions associated with RoActemra and requiring treatment discontinuation were reported in a total of 13 out of 3,778 patients (0.3%) treated with RoActemra during the controlled and open-label clinical studies. These reactions were generally observed during the second to fifth infusions of RoActemra. Fatal anaphylaxis has been reported after marketing authorisation during treatment with RoActemra IV.



## Frequently asked questions: RoActemra IV (continued)

### How frequently should I monitor the patient's vital signs?

Take the patient's vital signs before and after each infusion.

### What if patients cannot schedule their infusion in exactly 4 weeks?

RoActemra should be administered once every 4 weeks. Contact the prescriber for any deviations from that schedule.

### What information do I need to provide the patient about RoActemra?

Before beginning RoActemra therapy, it is important that you review the Package Leaflet with each patient. This contains valuable information that will help your patients fully understand what they may expect from their treatment.

**If your patient would like more information about RoActemra, please direct them to contact [medinfo.uk@roche.com](mailto:medinfo.uk@roche.com) or to call 0800 328 1629.**

For full information, see the Summary of Product Characteristics (SmPC) and the Package Leaflet, which can be found on the on the Electronic Medicines Compendium (EMC) website: [www.medicines.org.uk/emc](http://www.medicines.org.uk/emc).



## Part II – Subcutaneous (SC) administration of RoActemra by injection using a pre-filled syringe

This section will walk you through the RoActemra injection process using a pre-filled syringe in 4 steps

### Before therapy begins

Before beginning RoActemra therapy, it is important that you review the Package Leaflet with each patient. This contains valuable information that will help your patients fully understand what they may expect from their treatment.

Prior to each injection, it is important that you review the pre-administration checklist found in the Package Leaflet with your patient and allow ample time to discuss any questions he or she may have.

- RoActemra alert cards and other information can be requested from your sales representative. If you have questions or concerns, please email [medinfo.uk@roche.com](mailto:medinfo.uk@roche.com) or call +44 (0)800 328 1629
- For full information, see the Summary of Product Characteristics (SmPC) and the Package Leaflet, which can be found on the Electronic Medicines Compendium (EMC) website: [www.medicines.org.uk/emc](http://www.medicines.org.uk/emc)



## 1. Gather all necessary supplies

You will need:

- One RoActemra pre-filled syringe at room temperature
- A well-lit, clean, flat surface
- Sharps container
- Alcohol pad/cleansing wipes
- Sterile cotton ball or gauze

## 2. Take baseline assessments

Take baseline assessments to ensure the patient is healthy enough to receive the injection.

Vital signs should include:

- Blood pressure
- Temperature
- Pulse

### Also ask the patient if they:

- Are taking other medicines. This includes prescription and non-prescription medications, vitamins and herbal supplements
- Are taking any other medications to treat RA such as: Methotrexate (MTX), Enbrel® (etanercept), Humira® (adalimumab), Remicade® (infliximab), MabThera® (rituximab), Orencia® (abatacept), Kineret® (anakinra), Cimzia® (certolizumab pegol), or Simponi® (golimumab)
- Have had any allergic reactions to previous medications, including RoActemra
- Are pregnant, might be pregnant, intend to become pregnant, or are breast feeding
- Have an infection or are being treated for an infection; have had or now have hepatitis or any disease of the liver; have a history of stomach ulcers or diverticulitis; have had or now have impaired lung function (e.g. interstitial lung disease)
- Have diabetes or other underlying conditions that may predispose them to infections
- Are planning or are scheduled to have surgery; have had a recent vaccination (such as a flu shot) or are scheduled to have one
- Have cancer, cardiovascular risk factors, such as raised blood pressure and raised cholesterol levels, or moderate to severe kidney function problems

Enbrel® is a registered trademark of Amgen Inc. and Pfizer Inc.; Humira® is a registered trademark of AbbVie; Remicade® is a registered trademark of Schering Plough Corporation; MabThera® is a registered trademark of F. Hoffmann-La Roche Ltd; Orencia® is a registered trademark of Bristol-Myers Squibb; Kineret® is a registered trademark of Amgen Inc.; Cimzia® is a registered trademark of the UCB Group of Companies; Simponi® is a registered trademark of Centocor Inc. and Schering-Plough Corporation.

### 3. Preparation for injection with the pre-filled syringe

- Prior to the injection, inform the patient that serious allergic reactions including anaphylaxis have been reported in association with RoActemra. Such reactions may be more severe, and potentially fatal in patients who have experienced allergic reactions during previous treatment with RoActemra even if they have received premedication with steroids and antihistamines. Most allergic reactions occur within 24 hours of RoActemra administration, although allergic reactions can occur at any time. Fatal anaphylaxis has been reported after marketing authorisation during treatment with RoActemra IV
- If an anaphylactic reaction or other serious hypersensitivity reaction occurs, administration of RoActemra should be stopped immediately, appropriate therapy initiated and RoActemra should be permanently discontinued

### 3. Preparation for injection with the pre-filled syringe



- RoActemra 162 mg is supplied in 0.9 ml of solution for injection as a pack of 4 single-use pre-filled syringes. The pre-filled syringes should be stored at 2–8°C and should not be frozen. They should be kept in the outer carton to protect them from light and should be kept dry. The pre-filled syringes should be kept out of sight and reach of children. The expiry date should always be checked before use. The shelf life is 30 months.
- Inspect the pre-filled syringe visually for particulate matter and discolouration prior to administration and check the expiration date. Do not use if the medicine has expired, is cloudy or contains particles, is any colour besides colourless to slightly yellowish, or if any part of the pre-filled syringe appears to be damaged
- Once removed from the refrigerator, RoActemra 162 mg/0.9 ml must be administered within 8 hours and should not be kept above 30°C
- After removing from the refrigerator, the pre-filled syringe should be allowed to reach room temperature (18–28°C) by waiting for 25 to 30 minutes before injecting RoActemra 162 mg/0.9 ml. Do not warm up the pre-filled syringe in any other way
- The pre-filled syringe should not be shaken
- Wash your hands with soap and water
- Choose and prepare an injection site, preferably the front or middle of the thigh or lower part of the abdomen below the navel (except for the five centimetre area directly around the navel), and clean injection site with an alcohol pad. Let the skin dry for approximately 10 seconds. A different site should be used for subsequent injections
- Injections should never be given in moles, scars or areas where the skin is tender, bruised, red, hard, swollen or not intact. Do not inject into areas that could be bothered by a belt or waistband



• Patients should be assessed for their suitability to use RoActemra SC at home. Patients who are self-administering RoActemra should be advised to **seek immediate medical attention** if they experience any of the following signs or symptoms of systemic allergic reactions after receiving RoActemra:

- Rash, itching or hives
- Shortness of breath or trouble breathing
- Swelling of the lips, tongue or face
- Chest pain
- Feeling dizzy or faint
- Severe stomach pain or vomiting
- Hypotension


**If your patient has experienced any allergic reaction symptoms after their last dose of RoActemra they must NOT administer the next dose until they have informed you (their doctor/HCP) and you have told them to take the next dose.**

• Prior to the injection, inform the patient of potential injection site reactions. Most injection site reactions are mild-to-moderate in severity, do not necessitate drug discontinuation and usually resolve spontaneously. Injection site reaction symptoms include:

- Erythema
- Pruritus
- Pain
- Haematoma



#### 4. Administering the injection with the pre-filled syringe



##### Step 1 – Remove needle cap

When ready to inject, firmly grip the syringe with one hand and pull the cap straight off with the other hand. Discard the cap. Do not pull or press the plunger, and do not shake the pre-filled syringe. After removing the needle cap, the injection must be started within 5 minutes to prevent the medicine from drying out and blocking the needle. If the pre-filled syringe is not used within 5 minutes of removing the cap, you must dispose of it in a puncture resistant container and use a new pre-filled syringe. A small drop of liquid at the needle tip is normal.


**Never re-attach the needle cap after removal.**

##### Step 2 – Pinch skin and insert needle, release skin


Pinch the skin at the injection site to provide a firm surface for injection.

Insert the needle with a quick, firm action. The needle must be inserted all the way in at an angle between 45° and 90°.


Keep the syringe in position and release the pinched skin.



**It is important to choose the correct angle (between 45° and 90°) to ensure the medication is delivered under the skin, otherwise the injection could be painful and the medication may not be administered correctly.**







### Step 3 – Slowly press down all the way then remove

Slowly inject all the medicine by gently pushing the plunger all the way down.

Keep an even pressure on the plunger and don't release the pressure once the injection has started.

Once the plunger is pushed all the way down, keep pressing down on the plunger to be sure all of the medicine is injected before taking the needle out of the skin.

Keep pressing down on the plunger while you take the needle out of the skin at the same angle as inserted.

If, following insertion of the needle, you cannot depress the plunger, you must dispose of the pre-filled syringe in a puncture resistant container and use a new pre-filled syringe.

### Step 4 – Release plunger and dispose

Once the needle is completely removed from the skin, release the plunger. This will automatically activate the needle shield.

Press gently on the injection area with a cotton wool ball or gauze swab.

Throw away the used syringe in a sharps container.



If the plunger is not fully depressed the needle shield will not extend to cover the needle when it is removed, and the patient may not have received the full dose of RoActemra:

- **Do not** touch the needle shield of the pre-filled syringe to avoid a needle-stick injury
- **Do not** try to re-use the pre-filled syringe
- **Do not** repeat the injection with another pre-filled syringe



## Frequently asked questions

### How is the RoActemra pre-filled syringe supplied?

RoActemra 162 mg is supplied in 0.9 ml of solution for injection as a pack of 4 single-use pre-filled syringes.

### How do I store the RoActemra pre-filled syringe?

The pre-filled syringes should be stored at 2–8°C and should not be frozen. They should be kept in the outer carton to protect them from light and should be kept dry. The pre-filled syringes should be kept out of sight and reach of children.

### What is the shelf life of the RoActemra pre-filled syringe?

The shelf life is 30 months.

### How do I prepare the RoActemra pre-filled syringe for injection?

Do not shake the pre-filled syringe. Inspect the pre-filled syringe visually through the viewing window for particulate matter and discolouration prior to administration and check the expiration date. Do not use if the medicine is cloudy or contains particles, is any colour besides colourless to slightly yellowish, or if any part of the pre-filled syringe appears to be damaged. Once removed from the refrigerator, RoActemra 162 mg/0.9 ml must be administered within 8 hours and should not be kept above 30°C.

- After removing from the refrigerator, the pre-filled syringe must be allowed to reach room temperature (18–28°C) by waiting at least 25–30 minutes before injecting RoActemra 162 mg/0.9 ml. Do not warm up the pre-filled syringe in any other way.

### How do I prepare for injection and choose an appropriate injection site?

Wash your hands with soap and water. Choose an injection site, preferably the middle of the front thigh or lower part of the abdomen below the navel (except for the five centimetre area directly around the navel), and clean the injection site with an alcohol pad. Let the skin dry for approximately 10 seconds. A different site should be used for subsequent injections. Do not inject into moles, scars, or areas where the skin is tender, bruised, red, hard, swollen or not intact. Do not inject into areas that could be bothered by a belt or waistband.

### What do I need to inform the patient of prior to injection?

Patients should be assessed for their suitability to use RoActemra SC at home. Prior to the injection, inform the patient that serious allergic reactions including anaphylaxis have been reported in association with RoActemra. Such reactions may be more severe, and potentially fatal in patients who have experienced allergic reactions during previous treatment with RoActemra even if they have received premedication with steroids and antihistamines. Most allergic reactions occur within 24 hours of RoActemra administration, although allergic reactions can occur at any time. Fatal anaphylaxis has been reported after marketing authorisation during treatment with RoActemra IV.

- Patients who are self-administering RoActemra should be advised to seek immediate medical attention if they experience any of the following signs or symptoms of systemic allergic reactions after receiving RoActemra:

- Rash, itching or hives
- Shortness of breath or trouble breathing
- Swelling of the lips, tongue or face
- Chest pain
- Feeling dizzy or faint
- Severe stomach pain or vomiting
- Hypotension

**If your patient has experienced any allergic reaction symptoms after their last dose of RoActemra they must NOT administer the next dose until they have informed you (their doctor/HCP) and you have told them to take the next dose.**

- Prior to the injection, inform the patient of potential injection site reactions. Most injection site reactions are mild-to-moderate in severity, do not necessitate drug discontinuation and usually resolve spontaneously. Injection site reaction symptoms include:

- Erythema
- Pruritus
- Pain
- Haematoma

#### What should I look for during and after the injection?

If the injection is administered at the clinic, watch the patient closely for any immediate signs or symptoms of an allergic reaction. If an anaphylactic reaction or other serious hypersensitivity reaction occurs, administration of RoActemra should be stopped immediately, appropriate therapy initiated and RoActemra should be permanently discontinued.

## Frequently asked questions (continued)



#### How do I open the pre-filled syringe?

Firmly grip the syringe with one hand and pull the cap straight off with the other hand. After removing the needle cap, the injection must be started within 5 minutes to prevent the medicine from drying out and blocking the needle. If the pre-filled syringe is not used within 5 minutes of removing the cap, you must dispose of it in a puncture resistant container and use a new pre-filled syringe. Never re-attach the needle cap after removal.

#### How do I start the injection with the pre-filled syringe?

Pinch the skin at the injection site to provide a firm surface for injection. Insert the needle with a quick, firm action. The needle must be inserted all the way in at an angle between 45° and 90°. Keep the syringe in position and release the pinched skin.

#### How should I inject the medicine?

Slowly inject all the medicine by gently pushing the plunger all the way down. When the plunger is all the way down, keep pressing down to be sure all the medication has been injected.

If, following insertion of the needle, you cannot depress the plunger, you must dispose of the pre-filled syringe in a puncture resistant container and use a new pre-filled syringe.

#### How should I remove the needle from the skin?

Keep the plunger pushed down while you take the needle out of the skin at the same angle it was inserted.

#### What should I do when the needle is completely removed from the skin?

Once the needle is completely removed from the skin, release the plunger, allowing the needle-shield to protect the needle. Throw away the used syringe in a sharps container.

**If your patient would like more information about RoActemra, please direct them to contact [medinfo.uk@roche.com](mailto:medinfo.uk@roche.com) or to call +44 (0)800 328 1629.**

For full information, see the Summary of Product Characteristics (SmPC) and the Package Leaflet, which can be found on the Electronic Medicines Compendium (EMC) website: [www.medicines.org.uk/emc](http://www.medicines.org.uk/emc).

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.

Reporting forms and information can be found at [www.medicinesauthority.gov.mt/adrportal](http://www.medicinesauthority.gov.mt/adrportal) and sent by email to [postlicensing.medicinesauthority@gov.mt](mailto:postlicensing.medicinesauthority@gov.mt) or posted to ADR Reporting, The Medicines Authority Post-Licensing Directorate, 203, Level 3, Rue D'Argens, Gzira GZR 1368, MALTA. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing [welwyn.uk\\_dsc@roche.com](mailto:welwyn.uk_dsc@roche.com) or calling +44(0)1707 367554.

As RoActemra is a biological medicine, healthcare professionals should report adverse reactions by brand name and batch number.

